Evidence map›Paper›PMID 38962052›Full record

ArticleInternational cancer conference journal2024

Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases.

Yuki Kawaguchi, Yuko Watanabe, Yasuji Miyakita, Makoto Ohno, Chitose Ogawa, Masamichi Takahashi, Shunsuke Yanagisawa, Takayuki Mukai, Hiroshi Igaki, Hirokazu Sugino and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuki KawaguchiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Yuko WatanabeDepartment of Pediatric Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Yasuji MiyakitaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Makoto OhnoDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Chitose OgawaDepartment of Pediatric Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Masamichi TakahashiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Shunsuke YanagisawaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Takayuki MukaiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Hirokazu SuginoDepartment of Diagnostic Pathology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Akihiko YoshidaDepartment of Diagnostic Pathology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.ORCID 0000-0003-4303-6006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A combination of BRAF and MEK inhibitors is reported to be effective for gliomas with the BRAF V600E mutation; however, its efficacy in gliomas with leptomeningeal metastases (LMM) is still unknown. In this report, we describe two pediatric patients with high-grade glioma featuring the BRAF V600E mutation who were treated with dabrafenib and trametinib for LMM. Both 2 cases underwent craniotomy for primary intracranial lesions and were diagnosed as a high-grade glioma with BRAF V600E mutation; one case was consistent with anaplastic pleomorphic xanthoastorocytoma, the other was epithelioid glioblastoma. They received standard treatment for the lesions but subsequently were found to have new lesions including multiple spinal dissemination. We started administering dabrafenib and trametinib. Within a few days of starting treatment, the symptoms improved dramatically and MRI performed one month after the prescription of the two drugs demonstrated remission of both brain and spinal lesions. This report shows that dabrafenib and trametinib are effective not only for recurrent lesions but also for LMM in pediatric patients.

Indexed as

BRAFV600EDabrafenibEpithelioid glioblastomaPleomorphic xanthoastrocytomaTrametinib

Identifiers

PMID38962052
PMCPMC11217217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.